Vigilant Biosciences Raises $5.5 Million In Series B Funding

By Dan Anderson ● Mar 2, 2015

Miami, Florida based Vigilant Biosciences is a leading high-tech healthcare company that focuses on early detection and intervention of cancer. Vigilant Biosciences has raised $5.5 million in Series B funding from White Owl Capital Partners, venVelo, the Florida Institute for the Commercialization of Public Research, several existing investors, and several other angel and private investors. Vigilant Biosciences has now raised a total of $7.8 million in total funding.

Vigilant will be using the funding to drive towards CE Mark approval and U.S. regulatory approval for its OncAlert Oral Cancer Risk Assessment System. Plus the funds will also support the international product launch and commercialization of the OncAlert System along with other products in the company’s pipeline.

Vigilant’s OncAlert Oral Cancer Risk Assessment System is based on patented technology that detects protein markers known to indicate elevated risks for oral cancer even prior to visual and physical symptoms. The simple oral rinse procedure is easy to administer and is non-invasive for the patient.

“We are pleased at the excitement and confidence our investors show in the Company, our executive team, our products and the opportunity to positively impact the global cancer market,” said Vigilant Biosciences founder, chairman, and CEO Matthew H.J. Kim. “As hundreds of thousands continue to be diagnosed with oral cancer every year, we are committed to providing an accurate, effective and affordable way to aid in the early detection of risk for the disease. This funding will enable us to address this critical market need that has gone unmet for far too long.”